The global market for cancer-focused genetic testing services is on a transformative growth trajectory, with projections estimating a market size of USD 8,472.70 million by 2024, and an expected ...
Genetic testing, including germline and somatic, is vital for prostate cancer prognosis and personalized treatment strategies. PARP inhibitors, targeting BRCA mutations, are a promising therapy for ...
The past decade has witnessed a rapid expansion of genetic tests, including new instruments to inform patients who have been diagnosed with breast cancer about the risk of recurrence and to guide ...